NYKD Stock Overview
Nykode Therapeutics AS, a clinical-stage biopharmaceutical company, discovers and develops novel immunotherapies.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Nykode Therapeutics AS Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr13.41 |
| 52 Week High | kr30.86 |
| 52 Week Low | kr12.38 |
| Beta | 1.41 |
| 1 Month Change | -7.90% |
| 3 Month Change | -27.94% |
| 1 Year Change | -45.31% |
| 3 Year Change | -83.55% |
| 5 Year Change | n/a |
| Change since IPO | -32.27% |
Recent News & Updates
Recent updates
Earnings Update: Nykode Therapeutics AS (OB:NYKD) Just Reported Its Annual Results And Analysts Are Updating Their Forecasts
Mar 02
Risks To Shareholder Returns Are Elevated At These Prices For Nykode Therapeutics AS (OB:NYKD)
Jan 22We Think Nykode Therapeutics (OB:NYKD) Can Easily Afford To Drive Business Growth
Aug 20Nykode Therapeutics (OB:NYKD) Is In A Strong Position To Grow Its Business
Apr 06Could The Vaccibody AS (OB:VACC) Ownership Structure Tell Us Something Useful?
Jan 25
Shareholder Returns
| NYKD | NO Biotechs | NO Market | |
|---|---|---|---|
| 7D | 4.5% | 0.4% | -0.5% |
| 1Y | -45.3% | -76.3% | 2.9% |
Return vs Industry: NYKD exceeded the Norwegian Biotechs industry which returned -76.3% over the past year.
Return vs Market: NYKD underperformed the Norwegian Market which returned 2.9% over the past year.
Price Volatility
| NYKD volatility | |
|---|---|
| NYKD Average Weekly Movement | 7.2% |
| Biotechs Industry Average Movement | 10.2% |
| Market Average Movement | 5.1% |
| 10% most volatile stocks in NO Market | 10.5% |
| 10% least volatile stocks in NO Market | 2.9% |
Stable Share Price: NYKD's share price has been volatile over the past 3 months.
Volatility Over Time: NYKD's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 172 | Michael Engsig | nykode.com |
Nykode Therapeutics AS, a clinical-stage biopharmaceutical company, discovers and develops novel immunotherapies. The company develops vaccines for the treatment cancer and infectious diseases. Its lead product candidates include VB10
Nykode Therapeutics AS Fundamentals Summary
| NYKD fundamental statistics | |
|---|---|
| Market cap | kr4.38b |
| Earnings (TTM) | -kr385.62m |
| Revenue (TTM) | kr146.15m |
30.0x
P/S Ratio-11.4x
P/E RatioIs NYKD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NYKD income statement (TTM) | |
|---|---|
| Revenue | US$13.32m |
| Cost of Revenue | US$0 |
| Gross Profit | US$13.32m |
| Other Expenses | US$48.48m |
| Earnings | -US$35.15m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 14, 2024
| Earnings per share (EPS) | -0.11 |
| Gross Margin | 100.00% |
| Net Profit Margin | -263.86% |
| Debt/Equity Ratio | 0% |
How did NYKD perform over the long term?
See historical performance and comparison